Salarius Pharmaceuticals (SLRX) Stock Analysis

What Salarius Pharmaceuticals does

Salarius Pharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to advancing epigenetic-based cancer therapies. Its flagship investigational product, Seclidemstat (SP-2577), a small molecule inhibitor, is currently undergoing Phase I/II clinical evaluation. This compound is being developed to treat Ewing sarcoma and a range of advanced solid tumors. Another promising program involves SP-3164, a small molecule protein degrader designed to target both hematological and solid malignancies. The company has cultivated several key alliances. These include an exclusive licensing agreement with The University of Utah Research Foundation for the intellectual property associated with SP-2577 and related compounds. A collaboration with HLB Life Sciences grants rights for the comprehensive development, production, and commercialization of the drug in South Korea. Furthermore, Salarius partners with the Cancer Prevention and Research Institute of Texas (CPRIT) to accelerate product development activities. A research collaboration with the Cancer Epigenetics Institute at Fox Chase Cancer Center aims to uncover new indications and biomarkers for SP-2577. Corporate operations are managed from its headquarters in Houston, Texas.

Key metrics

ETFs linked to SLRX

Broad-market and Healthcare sector ETFs an investor holding Salarius Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how SLRX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Salarius Pharmaceuticals?

Salarius Pharmaceuticals trades under the ticker SLRX on NASDAQ.

Which exchange is SLRX listed on?

SLRX is listed on NASDAQ.

What sector does Salarius Pharmaceuticals operate in?

Salarius Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze SLRX in a portfolio?

PortView shows SLRX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.